CN1165298C - 化合物作为抗菌剂的新用途 - Google Patents

化合物作为抗菌剂的新用途 Download PDF

Info

Publication number
CN1165298C
CN1165298C CNB008082162A CN00808216A CN1165298C CN 1165298 C CN1165298 C CN 1165298C CN B008082162 A CNB008082162 A CN B008082162A CN 00808216 A CN00808216 A CN 00808216A CN 1165298 C CN1165298 C CN 1165298C
Authority
CN
China
Prior art keywords
use according
proton pump
releasing
alkyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008082162A
Other languages
English (en)
Chinese (zh)
Other versions
CN1354658A (zh
Inventor
A
A·埃克
J·劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902027A external-priority patent/SE9902027D0/xx
Priority claimed from SE9904704A external-priority patent/SE9904704D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1354658A publication Critical patent/CN1354658A/zh
Application granted granted Critical
Publication of CN1165298C publication Critical patent/CN1165298C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB008082162A 1999-06-01 2000-05-25 化合物作为抗菌剂的新用途 Expired - Fee Related CN1165298C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9902027A SE9902027D0 (sv) 1999-06-01 1999-06-01 New use
SE99020273 1999-06-01
SE9904704A SE9904704D0 (sv) 1999-12-21 1999-12-21 New use
SE99047045 1999-12-21

Publications (2)

Publication Number Publication Date
CN1354658A CN1354658A (zh) 2002-06-19
CN1165298C true CN1165298C (zh) 2004-09-08

Family

ID=26663588

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008082162A Expired - Fee Related CN1165298C (zh) 1999-06-01 2000-05-25 化合物作为抗菌剂的新用途

Country Status (27)

Country Link
US (2) US6593339B1 (https=)
EP (1) EP1196155B1 (https=)
JP (1) JP4818516B2 (https=)
KR (1) KR100671392B1 (https=)
CN (1) CN1165298C (https=)
AR (1) AR024159A1 (https=)
AT (1) ATE272396T1 (https=)
AU (1) AU780678B2 (https=)
BG (1) BG106158A (https=)
BR (1) BR0011116A (https=)
CA (1) CA2373653C (https=)
CZ (1) CZ20014289A3 (https=)
DE (1) DE60012745T2 (https=)
EE (1) EE200100647A (https=)
HK (1) HK1045814B (https=)
HU (1) HUP0201502A3 (https=)
IL (1) IL146407A0 (https=)
IS (1) IS6185A (https=)
MX (1) MXPA01012295A (https=)
NO (1) NO20015855L (https=)
NZ (1) NZ515317A (https=)
PL (1) PL352744A1 (https=)
RU (1) RU2252032C2 (https=)
SK (1) SK17392001A3 (https=)
TR (1) TR200103474T2 (https=)
TW (1) TWI243672B (https=)
WO (1) WO2000072838A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297260B1 (en) 1998-10-30 2001-10-02 Nitromed, Inc. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
AP2002002582A0 (en) 1999-12-23 2002-09-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
AU2002305758B2 (en) 2001-06-01 2006-09-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20070021345A1 (en) * 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2487414A1 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP2005535642A (ja) 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
AU2003247792B2 (en) 2002-07-03 2009-09-24 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
US7244753B2 (en) 2002-07-29 2007-07-17 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1534278A4 (en) 2002-08-01 2006-09-06 Nitromed Inc NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
AU2003283096A1 (en) * 2002-11-05 2004-06-07 Merck Frosst Canada And Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) * 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
SE0301880D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Uk Ltd New drug delivery composition
US20050054714A1 (en) * 2003-07-17 2005-03-10 Benito Munoz Nitric oxide releasing drugs for Alzheimer's disease
EP1663199B1 (en) 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) * 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
WO2006027780A2 (en) * 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
AU2006274098B2 (en) * 2005-07-26 2012-02-09 Nicox Science Ireland Pharmaceutical formulation of nitrooxyderivatives of NSAIDs
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
KR20120030106A (ko) 2009-06-25 2012-03-27 아스트라제네카 아베 Nsaid-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
TW201225972A (en) 2010-11-15 2012-07-01 Univ Ramot Dipeptide analogs for treating conditions associated with amyloid fibril formation
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
CN104815330A (zh) * 2015-05-22 2015-08-05 杜林� 乙酸类非甾体抗炎药的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IL98680A0 (en) 1991-06-30 1992-07-15 Yeda Res & Dev Hydroxamate derivatives and pharmaceutical compositions containing them
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
EP0722434B1 (en) 1993-10-06 1998-07-29 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
WO1995009612A1 (en) * 1993-10-07 1995-04-13 Entremed, Inc. Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
WO1995030641A1 (en) * 1994-05-10 1995-11-16 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5785689A (en) 1996-07-18 1998-07-28 Act Medical, Inc. Endoscopic catheter sheath position control
EP0941101A1 (en) * 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents

Also Published As

Publication number Publication date
NO20015855L (no) 2002-01-30
KR100671392B1 (ko) 2007-01-22
EP1196155A1 (en) 2002-04-17
TWI243672B (en) 2005-11-21
EE200100647A (et) 2003-02-17
DE60012745D1 (de) 2004-09-09
EP1196155B1 (en) 2004-08-04
US20040048917A1 (en) 2004-03-11
CA2373653C (en) 2011-03-15
JP2003500442A (ja) 2003-01-07
HK1045814A1 (en) 2002-12-13
BG106158A (en) 2002-06-28
AR024159A1 (es) 2002-09-04
CA2373653A1 (en) 2000-12-07
IL146407A0 (en) 2002-07-25
PL352744A1 (en) 2003-09-08
CZ20014289A3 (cs) 2002-05-15
RU2252032C2 (ru) 2005-05-20
AU780678B2 (en) 2005-04-07
BR0011116A (pt) 2002-02-19
CN1354658A (zh) 2002-06-19
HUP0201502A2 (en) 2002-08-28
IS6185A (is) 2001-11-29
HK1045814B (en) 2005-04-01
SK17392001A3 (sk) 2002-07-02
NZ515317A (en) 2004-05-28
JP4818516B2 (ja) 2011-11-16
AU5262300A (en) 2000-12-18
NO20015855D0 (no) 2001-11-30
ATE272396T1 (de) 2004-08-15
HUP0201502A3 (en) 2003-03-28
MXPA01012295A (es) 2002-07-30
WO2000072838A1 (en) 2000-12-07
TR200103474T2 (tr) 2002-04-22
KR20020015334A (ko) 2002-02-27
US6593339B1 (en) 2003-07-15
DE60012745T2 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
CN1165298C (zh) 化合物作为抗菌剂的新用途
CN1248683C (zh) 二肽基肽酶iv抑制剂在制备治疗2型糖尿病的药物中的用途
CN1622805A (zh) 包含止泻药和埃坡霉素或埃坡霉素衍生物的组合
CN1178648C (zh) H+ 、k+ -atp酶抑制剂在制备用于增强抑制胃酸分泌的口服药物中的用途
CN87105828A (zh) 苏灵大或苏灵大钠和碱的速效组合物
CN1311675A (zh) 具有lgE影响性能的化合物
CN1774253A (zh) 用环氧丙酯酮衍生物治疗顽固性肿瘤
CN1516600A (zh) 用于治疗肿瘤疾病的联合药物
CN1148188C (zh) 镇痛剂
CN1268135A (zh) 螺杆菌属感染引起的疾病的预防/治疗剂
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
CN1882328A (zh) 使用含内过氧化物桥的化合物治疗幽门螺杆菌相关疾病的方法和组合物
CN1101189C (zh) 含有1-甲基碳青霉烯衍生物作为活性成分的抗幽门螺杆菌组合物
CN1270517A (zh) 抗菌剂
CN1842328A (zh) 可用作抗炎剂的α-氨基酰胺衍生物
CN1874772A (zh) 治疗隐匿性胃食管反流的咪唑并[1,2-a]吡啶衍生物
CN1592615A (zh) 含有二甲双胍和4-氧代丁酸的药物组合物及其在治疗糖尿病中的用途
CN1496259A (zh) 新用途
JP2003517434A5 (https=)
CN1917865A (zh) 有机化合物的组合
EP1881826B1 (en) Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)
CN1625396A (zh) 化合物尤其是卤代乙酰胺苯甲酸的脲衍生物或酯衍生物及其于治疗寄生疾病的用途
CN1430511A (zh) 存活效益
CN1589154A (zh) 含有血管紧张肽ii受体拮抗剂的药用组合物
CN1599608A (zh) 含有格列酮和4-氧代丁酸的药物组合物以及它们治疗糖尿病的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NICOX S. A.

Free format text: FORMER OWNER: ASTRAZENCA AB

Effective date: 20051118

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20051118

Address after: French Sophia Antti Boris

Patentee after: Nicox S. A.

Address before: Swedish Sodertalje

Patentee before: Astra Zeneca Aktiebolag

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040908

Termination date: 20110525